Chinese political body wants more progress on hospital reforms


The pace of hospital reforms in China needs to go faster as patient access to services continues to lag and costs are not under control--with the insurance reimbursement system a focus.

News service said those issues prompted a fresh wave of proposals to the Chinese People's Political Consultative Conference (CPPCC) National Committee, the country's top political advisory body.

Among the suggestions is a new system of insurance payments that would fund hospitals to pay staff better and avoid reliance on markups for prescription drugs sold on site as a primary revenue source, the online news site said citing a statement from the CPPCC.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

In April, the government announced subsidies to expand a program to wean public hospitals from markups on drugs sold on site to now cover 200 public hospitals from 100 currently.

But as points out, the many rural hospitals and clinics fall outside the pilot, making it necessary to consider how to shift insurance payments to community clinics.

China is trying to target subsidies as part of a broad effort to restructure healthcare delivery. Doctors at major public hospitals face increasing patient loads and low pay, while patients may have to endure long waiting times for a consultation.

- here's the Xinhua story from


Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.